Business Context and Reporting Period
This Form 6-K was filed by China SXT Pharmaceuticals, Inc. on May 17, 2021, covering the month of May 2021. The filing serves as a current report regarding the termination of a previously announced securities purchase agreement (SPA) and voting agreements dated February 8, 2021, between the Company and Xiaodong Ji.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and transactional updates rather than financial performance data.
Material Changes
- Termination of Transaction: The Company and Mr. Ji agreed to terminate the SPA and voting agreements on May 8, 2021. The transaction failed to close because the purchaser did not deliver the aggregate purchase price as required.
- Board Composition: Mr. Ji was previously approved to serve as a director effective upon the closing of the transaction. Due to the termination, Mr. Ji will not serve as a director of the Company.
Guidance, Outlook, and Risks
The filing includes a special note regarding forward-looking statements, cautioning that actual results may differ materially from expectations. Key risks and uncertainties identified include:
- The impact of the COVID-19 outbreak on product demand, operational duration, and recovery pace.
- The ability to implement cost containment and business recovery strategies.
- Adverse effects on the market price of ordinary shares.
- Changes in technology, economic conditions, government regulations, and competition in China.
The Company explicitly states it undertakes no duty to update forward-looking statements after the date of this report.
Investor Verification Checklist
- Confirm the final status of the terminated SPA with Xiaodong Ji and any potential legal or financial repercussions.
- Verify the current composition of the Board of Directors following Mr. Ji's exclusion.
- Review subsequent filings for updated financial data, as this report contains no operational metrics.
- Monitor the Company's specific strategies for mitigating COVID-19 related risks as outlined in the forward-looking statement.